We love to hear from our listeners. Send us a message. On this week's episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing innovative solid tumor treatments that target functional proteins in the tumor micro-environment. Chetboun talks about raising money for preclinical research and navigating the valley of death between research and clinical development, accessing French innovation funding and angel networks, how click chemistry can produce therapies at a lower cost compared to antibody-drug conjugates (ADCs), and the potential use of drug combinations and umbrella trials for testing multiple cancer indications. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions :
[email protected] Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/
